

EPV0944

Acute psychosis with compulsive behaviour caused by hypothyroidism: a case reportI. Ilgen Erdem¹, F. Alioglu Karayilan^{2*} and B. Kalay Demirci¹¹Psychiatry, Karabuk University and ²Psychiatry, Private Praxis, Karabuk, Türkiye

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.2242

Introduction: Hypothyroidism is a common problem in clinical practice which can be seen with diverse psychiatric manifestations.**Objectives:** Here we report a case of psychosis with compulsive behavior in a 46-year-old man who had no previous history of psychiatric disorder was brought to the emergency department by his family.**Methods:** During his evaluation, he described visual and auditory hallucinations. In addition, it was observed that dermatitis developed on her hands and around his mouth due to compulsive washing behavior. It was learned that he was diagnosed with hypothyroidism 2 months ago but he was not taking his medication. He was admitted inpatient clinic for 39 days and consulted to an endocrinologist. Inpatient treatment was initiated with haloperidol 10mg PO and levothyroxine. Given the persistence of irregular intake, it was decided to switch to haloperidol long-acting treatment.**Results:** After only requiring both antipsychotic drugs and thyroxine replacement our patient showed progressive clinical recovery attaining full remission within 5 weeks.**Conclusions:** It was clear that physicians should be aware of the possible different manifestations of endocrinologic disorders. All patients presenting with a first episode psychosis and compulsive behavior should be screened for thyroid dysfunction**Disclosure of Interest:** None Declared

EPV0945

How sexuality is affected and managed in patients under antipsychotic drugsF. Ribeirinho Soares^{1*}, B. Mesquita², A. M. Fraga¹, M. Albuquerque¹, J. O. Facucho¹, P. E. Santos¹, D. E. Sousa¹, N. Moura³ and P. Cintra¹¹Departamento de Saúde Mental, Hospital de Cascais, Cascais;²Departamento de Saúde Mental, Hospital de Cascais, Porto and³Departamento de Saúde Mental, Centro Hospitalar Barreiro Montijo, Barreiro, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.2243

Introduction: Sexual dysfunction (SD) is a prevalent side effect of antipsychotic drugs (AP), and it impairs patients' quality of life. Because of the distress caused by it, it should be borne in mind when prescribed since it is responsible for treatment nonadherence or discontinuation. SD affects about 45- 80% of males and 30-80% of females that take it. In SD, all phases of the sexual response cycle may be compromised.**Objectives:** This non-systematic review of the literature aims to better understand the antipsychotic-induced SD and its

management to better compliance of AP-treated patients without compromising their quality of life.

Methods: A semi-structured review on PubMed linking SD as a side effect of AP drugs.**Results:** All AP drugs can cause SD. It seems related to their mechanism of activity at receptors D2, 5-HT₂, α 1, H1, and M, which are also involved in sexual function. They do it by diminishing arousal, decreasing libido by blocking motivation and reward system and orgasm indirectly, provoking erectile dysfunction by vasodilatation, and decreasing woman lubrication. Hyperprolactinemia is a significant cause of sexual dysfunctions. Haloperidol, Risperidone, and Amisulpride (prolactin elevating AP) are more likely to cause SD than Olanzapine, Clozapine, Quetiapine, and Aripiprazole (prolactin sparing AP). Although psychotic disorders (Schizophrenia and other psychotic disorders) can impact sexual functioning, according to evidence, there is no denying the role of AP in this issue. Aripiprazole, a D2 partial agonist, has been associated with lower rates of SD and seems to reduce the rates of SD in patients previously treated with other AP. Other AP with the same potential dopamine agonist activity, such as Cariprazine and Brexpiprazole, can probably have the same effect. The management of SD induced by AP drugs should include measuring serum prolactin and modifying risk factors like hypertension, smoking, hyperglycemia, and hypercholesterolemia. In that regard, waiting for spontaneous remission, reducing the dose of the AP prescribed, or switching to Aripiprazole are all viable strategies, if possible. Although the evidence supporting the addition of symptomatic therapies is weak, adding dopaminergic drugs (amantadine, bromocriptine, cabergoline) or drugs with specific effects on sexual functioning (such as phosphodiesterase inhibitors or yohimbine) may be helpful in selected cases.**Conclusions:** Although all AP drugs can cause sexual dysfunction, it is difficult to determine its true prevalence accurately. AP-induced sexual dysfunction can adversely affect compliance and is one of the factors that must be considered when selecting treatment. In summarizing, Aripiprazole has shown to be the AP with the most favorable profile concerning SD. Cariprazine and Brexpiprazole, being also D2 partial agonists, may cause less SD.**Disclosure of Interest:** None Declared

EPV0946

A Case Report of Complex Clozapine Initiation Despite ContraindicationsG. Dumais-Lévesque^{1,2*}, L. Béchard^{2,3,4}, E. Malenfant^{2,3}, M.-F. Demers^{2,3,4} and A.-P. Bouffard^{1,2}¹Psychiatry and Neurosciences, University Laval; ²University Institute of Mental Health in Quebec; ³Pharmacy Faculty, University Laval and ⁴CERVO Research Center, Quebec, Canada

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.2244

Introduction: Clozapine is well known for its unique efficacy in treatment-resistant schizophrenia and to reduce violent behaviour. Unfortunately, life-threatening adverse reactions including ileus, myocarditis and agranulocytosis can hinder its use. In this context, some clinicians may be reluctant to initiate clozapine in patients who are prone to these adverse drug reactions.